These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 22586610)
1. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Herman AG; Hayano M; Poyurovsky MV; Shimada K; Skouta R; Prives C; Stockwell BR Cancer Discov; 2011 Sep; 1(4):312-25. PubMed ID: 22586610 [TBL] [Abstract][Full Text] [Related]
2. Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells. Wu W; Xu C; Ling X; Fan C; Buckley BP; Chernov MV; Ellis L; Li F; Muñoz IG; Wang X Cell Death Dis; 2015 Dec; 6(12):e2035. PubMed ID: 26720344 [TBL] [Abstract][Full Text] [Related]
3. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells. Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850 [TBL] [Abstract][Full Text] [Related]
4. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53. Wang L; He G; Zhang P; Wang X; Jiang M; Yu L Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547 [TBL] [Abstract][Full Text] [Related]
5. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase. Xu C; Fan CD; Wang X Oncogene; 2015 Jan; 34(3):281-9. PubMed ID: 24413081 [TBL] [Abstract][Full Text] [Related]
6. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. Okamoto K; Taya Y; Nakagama H FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542 [TBL] [Abstract][Full Text] [Related]
7. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53. Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260 [TBL] [Abstract][Full Text] [Related]
8. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2. Nie J; Xie P; Liu L; Xing G; Chang Z; Yin Y; Tian C; He F; Zhang L J Biol Chem; 2010 Jul; 285(30):22818-30. PubMed ID: 20484049 [TBL] [Abstract][Full Text] [Related]
9. p53 regulation: teamwork between RING domains of Mdm2 and MdmX. Wang X Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240 [TBL] [Abstract][Full Text] [Related]
10. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors. Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030 [TBL] [Abstract][Full Text] [Related]
11. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity. Ranaweera RS; Yang X J Biol Chem; 2013 Jun; 288(26):18939-46. PubMed ID: 23671280 [TBL] [Abstract][Full Text] [Related]
12. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. Wang X; Wang J; Jiang X J Biol Chem; 2011 Jul; 286(27):23725-34. PubMed ID: 21572037 [TBL] [Abstract][Full Text] [Related]
13. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Hu B; Gilkes DM; Chen J Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722 [TBL] [Abstract][Full Text] [Related]
14. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148 [TBL] [Abstract][Full Text] [Related]
15. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179 [TBL] [Abstract][Full Text] [Related]
16. Mdm2 and MdmX partner to regulate p53. Wang X; Jiang X FEBS Lett; 2012 May; 586(10):1390-6. PubMed ID: 22673503 [TBL] [Abstract][Full Text] [Related]
17. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach. Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787 [TBL] [Abstract][Full Text] [Related]
18. Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2. Singh RK; Iyappan S; Scheffner M J Biol Chem; 2007 Apr; 282(15):10901-7. PubMed ID: 17301054 [TBL] [Abstract][Full Text] [Related]
19. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Kawai H; Wiederschain D; Yuan ZM Mol Cell Biol; 2003 Jul; 23(14):4939-47. PubMed ID: 12832479 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation. Ghosh M; Huang K; Berberich SJ Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]